Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Next Previous
Trial Profile

A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 17 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fulzerasib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms KROCUS
  • Sponsors GenFleet Therapeutics

Most Recent Events

  • 04 Jun 2024 Results ( As of Jan. 30, 2024, a total of 27 pts) evaluating effects of KRAS G12C inhibitor combined with an anti-EGFR antibody in NSCLC pts as front-line treatment., presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 01 Jun 2024 According to GenFleet Therapeutics media release, as of 19 Apr 2024, a total of 40 subjects were enrolled and 33 of them received at least one available post-treatment tumor assessment.
  • 01 Jun 2024 According to GenFleet Therapeutics media release, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with cetuximab for first-line non-small cell lung cancer (NSCLC) treatment, at the 2024 American Society of Clinical Oncology (ASCO) annual meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top